Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Arjo AB (publ) (ARJO-B.ST)
SEK27.00
+0.92 (+3.53%)
SE STO Healthcare Medical - Distribution
Address
Hans Michelsensgatan 10 201 20
Malmö, SE
Malmö, SE
CEO
Andreas Elgaard
Website
arjo.com
IPO
2017-12-12
ISIN SE0010468116
Also trades on
Other OTC · ARRJF (USD)
Stockholm Stock Exchange · ARJO-B.ST (SEK)
Description
Arjo AB (publ) is a global leader in providing medical devices and innovative solutions tailored for patients experiencing limited mobility and age-related health conditions. Operating across North America, Western Europe, and other international markets, the company's comprehensive offerings span safe patient handling, hygiene and disinfection products, specialized medical beds, and technologies for the prevention and treatment of pressure injuries, leg ulcers, deep vein thrombosis, and edema. They also supply equipment for obstetric and cardiac diagnostics. Complementing its product range, Arjo delivers valuable services such as specialized room assessments for dementia and bariatric care, clinical consulting, equipment maintenance, and flexible rental and financing options. Their diverse client base comprises both private and public institutions engaged in acute and long-term healthcare. Founded in 1957, Arjo AB (publ) is headquartered in Malmö, Sweden.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
SEK27.00
+0.92 (+3.53%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
388.3K
Beta
0.68
Float Shares
170.68M
Free Float %
62.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.16% | -2.99% | +1.65% | -8.94% | -23.34% | -22.03% | -19.58% | -42.19% | -70.42% | +0.04% | +0.04% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
27.00
DCF (Unlevered)
79.47
+194.3%
DCF (Levered)
64.43
+138.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
40% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.10
Grey zone
Piotroski F-Score
5 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Distribution: +5.6%-2.6% Q1'26: -5.8% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%-32.8% Q1'26: +21.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+7.4% Q1'26: +5.9% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+6.1% ★ Q1'26: +7.0% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+4.0% Q1'26: +4.5% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×2.96× Q1'26: 2.95× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 5 EPS Ana. |
Dec 2027 5 Rev. Ana. 5 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.69B
est: 7.70B (-0.1%)
|
8.22B
est: 8.22B (0.0%)
|
8.93B
est: 8.92B (+0.0%)
|
9.08B
est: 9.05B (+0.3%)
|
9.07B
est: 9.10B (-0.3%)
|
9.98B
est: 10.00B (-0.2%)
|
10.98B
est: 11.23B (-2.2%)
|
11.29B
est: 11.28B (+0.1%)
|
11.00B
est: 11.05B (-0.4%)
|
11.02B
10.97B – 11.07B
-0.3% YoY
|
11.43B
11.32B – 11.47B
+3.7% YoY
|
11.81B
11.80B – 11.81B
+3.3% YoY
|
12.05B
11.96B – 12.10B
+2.1% YoY
|
| EBITDA |
936.00M
est: 1.47B (-36.2%)
|
1.17B
est: 1.57B (-25.5%)
|
1.68B
est: 1.70B (-1.4%)
|
1.82B
est: 1.72B (+5.4%)
|
2.03B
est: 1.73B (+17.2%)
|
1.70B
est: 1.91B (-10.8%)
|
1.96B
est: 2.06B (-4.7%)
|
2.03B
est: 2.07B (-2.0%)
|
1.81B
est: 2.03B (-10.6%)
|
2.02B
2.01B – 2.03B
-0.3% YoY
|
2.10B
2.08B – 2.10B
+3.7% YoY
|
2.17B
2.16B – 2.17B
+3.3% YoY
|
2.21B
2.19B – 2.22B
+2.1% YoY
|
| EBIT |
295.00M
est: 692.39M (-57.4%)
|
504.00M
est: 739.32M (-31.8%)
|
678.00M
est: 802.76M (-15.5%)
|
847.00M
est: 814.17M (+4.0%)
|
1.08B
est: 818.35M (+31.5%)
|
714.00M
est: 899.63M (-20.6%)
|
903.00M
est: 938.03M (-3.7%)
|
949.00M
est: 942.22M (+0.7%)
|
675.00M
est: 923.34M (-26.9%)
|
920.91M
916.49M – 925.30M
-0.3% YoY
|
954.75M
945.72M – 958.55M
+3.7% YoY
|
986.62M
985.98M – 987.26M
+3.3% YoY
|
1.01B
999.75M – 1.01B
+2.1% YoY
|
| Net Income |
118.00M
est: 418.73M (-71.8%)
|
296.00M
est: 481.19M (-38.5%)
|
403.00M
est: 460.52M (-12.5%)
|
526.00M
est: 605.16M (-13.1%)
|
742.00M
est: 803.87M (-7.7%)
|
449.00M
est: 528.59M (-15.1%)
|
480.00M
est: 513.00M (-6.4%)
|
498.00M
est: 572.40M (-13.0%)
|
334.00M
est: 551.19M (-39.4%)
|
482.01M
439.51M – 528.14M
-12.6% YoY
|
568.52M
498.67M – 646.76M
+17.9% YoY
|
665.92M
572.00M – 734.86M
+17.1% YoY
|
604.66M
599.03M – 608.10M
-9.2% YoY
|
| SGA |
2.71B
est: 2.55B (+6.1%)
|
2.88B
est: 2.72B (+5.6%)
|
3.02B
est: 2.96B (+2.1%)
|
3.05B
est: 3.00B (+1.8%)
|
2.98B
est: 3.01B (-1.3%)
|
3.30B
est: 3.31B (-0.5%)
|
3.63B
est: 3.71B (-2.4%)
|
3.75B
est: 3.73B (+0.4%)
|
3.67B
est: 3.66B (+0.5%)
|
3.65B
3.63B – 3.66B
-0.3% YoY
|
3.78B
3.74B – 3.80B
+3.7% YoY
|
3.91B
3.90B – 3.91B
+3.3% YoY
|
3.99B
3.96B – 4.00B
+2.1% YoY
|
| EPS |
0.43
est: 1.54 (-72.0%)
|
1.09
est: 1.77 (-38.3%)
|
1.48
est: 1.69 (-12.5%)
|
1.93
est: 2.22 (-13.1%)
|
2.72
est: 2.95 (-7.8%)
|
1.65
est: 1.94 (-15.0%)
|
1.76
est: 1.88 (-6.6%)
|
1.83
est: 2.11 (-13.1%)
|
1.23
est: 2.03 (-39.3%)
|
1.80
1.61 – 1.94
-11.2% YoY
|
2.11
1.83 – 2.37
+16.9% YoY
|
2.36
2.10 – 2.70
+12.3% YoY
|
2.22
2.20 – 2.23
-6.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-26 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-25 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-15 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-13 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
869.67M
OE per share TTM
3.19
Owner's Yield
12.96%
Maintenance CapEx ratio
112.69%
Maint CapEx / Avg PPE
26.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 67 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap Value ETF DISV | 0.08% | 3.58M | 0.42% |
| 2 | State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR Acc ZPRX.DE | 0.05% | 411.5K | 0.30% |
| 3 | iShares International Small-Cap Equity Factor ETF ISCF | 0.05% | 309.2K | 0.24% |
| 4 | iShares MSCI Europe Small-Cap ETF IEUS | 0.03% | 57.1K | 0.41% |
| 5 | Dimensional - International Small Cap ETF DFIS | 0.03% | 1.88M | 0.39% |
| 6 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.03% | 1.06M | 0.30% |
| 7 | Avantis International Small Cap Equity ETF AVDS | 0.02% | 75.3K | 0.30% |
| 8 | iShares $ Treasury Bond 3-7yr UCITS ETF CBUG.DE | 0.02% | 105.8K | 0.10% |
| 9 | UBS MSCI World Small Cap Socially Responsible UCITS ETF USD acc WSCSRI.SW | 0.02% | 160.0K | 0.23% |
| 10 | UBS MSCI World Small Cap Socially Responsible UCITS ETF USD dis WSCR.L | 0.02% | 159.9K | 0.23% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
103.8K
Shares Outstanding
272.37M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Andreas Elgaard | Chief Executive Officer, President & Director | 17M | male |
| Christofer Carlsson | Chief Financial Officer | — | male |
| Eva Brike | Executive Vice President of Human Resources & Sustainability | — | female |
| Ingrid Carlsson | Executive Vice President of Legal & Business Compliance and Board Secretary | — | female |
| Johan Ostblad | Head of Sustainability | — | male |
| Jonas Cederhage | Executive Vice President of Product Development, Supply Chain & Operations | — | — |
| Maria Fagerberg | Executive Vice President of Quality & Regulatory Compliance | — | female |
| Maria Nilsson | Executive Vice President of Communication & Public Relations | — | female |
| Nick Gabery Adams | Vice President of Brand Management & Marketing Communications | — | male |
| Sara Ehinger | Vice President of Investor Relations & Corporation Communications | — | — |
| Tobias Kramer | Executive Vice President of Global Marketing | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ARJO-B.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
